Prograf MDL Class Cert. Not Doomsday, 1st Circ. Hears

By Matthew Bultman (August 18, 2015, 2:08 PM EDT) -- The First Circuit should uphold a lower court's class certification ruling in litigation accusing Astellas Pharma US LLC of delaying entry of a generic form of its immunosuppressant Prograf, Public Justice PC said Monday, arguing the ruling isn't the doomsday scenario it has been made out to be....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!